MACK AND TRANSPORT ANNOUNCE DEVELOPMENT AGREEMENT FOR BREAKTHROUGH COLD SORE PRODUCT

Mack Molding Company and Transport Pharmaceuticals (Transport) announced today that they have entered into an agreement to provide development services for Transport's proprietary device/drug combination system that will be used to treat cold sores (herpes labialis), currently in Phase III clinical trials. Working together, the two companies will finalize the product design for the device. The newly redesigned device will be tested in a skin irritation study in February 2006 and in a pivotal Phase III trial to be initiated in 2Q 2006.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051012005188&newsLang=en)